Revolution in diabetes: Semaglutid beats new therapy for weight reduction!

Revolution in diabetes: Semaglutid beats new therapy for weight reduction!

China - Brightgene Pharmaceutical Co., Ltd. today presented promising phase 2 data at the 85th scientific conference of the American Diabetes Association (ADA) for their new dual GLP-1R/GRIPPONISTER BGM0504 and preclinical data on BGM1812. The latter is developed as the next Generation of the next generation to treat obesity. The results indicate that BGM0504 not only supports weight regulation, but also the metabolic risk in people with type 2 diabetes and overweight, non-obese people could significantly reduce. According to [ots.at] (https://www.ots.at/presseaus-sung/ots_20250624_ots0001/brightgene-pra and-positive-phase-fuer-Dual-Glp-1r) BGM0504 in the known drug Semaglutide has a superiority in weight reduction shown.

The phase 2 study carried out in people with type 2 diabetes was a multicenter, randomized, double-blind, placebo-controlled study with 67 participants aged 18 to 65. These were randomized in five groups (5 mg, 10 mg, 15 mg, semaglutid, placebo). The primary endpoint was the change in the HBA1C value after 12 weeks. The results of the study are remarkable: The HBA1C cuts were -1.72 % at 5 mg BGM0504, -1.94 % at 10 mg, and -2.48 % in 15 mg compared to -1.43 % in Semaglutid and -0.28 % in placebo.

weight reduction in obesity

Another phase 2 study on BGM0504 was carried out in obese adults. There, 120 volunteers were examined with a body mass index (BMI) of 24 kg/m² or more in a randomized, double-blind, placebo-controlled study. The results showed a significant waist circumference reduction between -8.0 cm and -12.98 cm as well as weight loss between -10.77 % and -19.78 % compared to the placebo group. In addition, there were considerable improvements in systolic blood pressure, which varied from -11.60 to -13.03 mmHg, and diastolic blood pressure, with decreases between -5.98 and -7.50 mmHg.

In a parallel preclinical study on BGM1812, strong receptor activations and dose-dependent weight acceptance in the dio rat model were observed. This shows promising results for the potential clinical application of this novelty. The combination of BGM1812 and BGM0504 turned out to be more effective in weight reduction as other combinations tested.

Studies on BGM0504

BGM0504 has proven itself in another randomized phase I study in healthy Chinese volunteers. This study examined security, tolerance, pharmacokinetics and pharmacodynamics. In particular, the investigation showed positive results in terms of glycemic control and was classified as generally safe and well -tolerated. The most common undesirable effects were gastrointestinal, such as nausea and diarrhea. These findings support the further development of BGM0504 for the treatment of type 2-diabetes mellitus and obesity, as described in pubmed.ncbi.nlm.nih.gov In view of the current number of illnesses, research on diabetes mellitus is particularly relevant. Almost 8.5 million people are affected in Germany, and this number could increase up to 12 million by 2040. With over 400 experts, the German Center for Diabetes Research (DZD) is working to decrypt the emergence of diabetes and to develop new prevention and therapy approaches. Current research results show that the brain plays an essential role in the development of type 2 diabetes and obesity, which opens up new research approaches (health research-bmbf.de.

The continuing research on innovative drugs and therapy approaches is crucial to effectively tackle the growing problem of diabetes and to improve the quality of life of those affected.